NCT06605664View on ClinicalTrials.gov

Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

September 30, 2031

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DIAGNOSTIC_TEST

Hyperpolarized 13C pyruvate MRI

The subject enrolled in this trial will receive DNP-MRI scanning for two times through hyperpolarized \[1-13C\]pyruvate injection (\~250 mM, 0.43 mL/Kg) before and 2-5 weeks after radiotherapy.

Trial Locations (1)

333

RECRUITING

Chang Gung Memorial Hospital at Linkou, Taoyuan

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER